Athelas

Athelas

A company developing blood testing device that utilizes deep learning and computer vision.

Athelas is developing technology to allow blood testing for neutrophils, lymphocytes, platelets, WBCs, morphology, and cell activation from less blood than is currently required. Athelas uses Computer Vision instead of traditional coulter counting or flow based cytometry. The company is based in Mountain View, CA.

The Athelas One for analysis of white blood cell and neutrophil percent is FDA approved for point-of-care indications. The device uses a finger prick of blood and completes analysis in minutes. The Athelas app for Android and iOS is used to deliver blood test results. The device is marketed for oncologists for monitoring oncology patients, life sciences researchers and for patients. The device can also be used to test for viral or bacterial infection and possibly predict cardiac arrest.

Exclusive Canadian rights for the Athelas One device was in-licensed by pharmaceutical company HLS Therapeutics. Athelas One is designed to enhance and simplify the mandatory safety blood monitoring process for patients prescribed CLOZARIL (clozapine) which is approved for Treatment Resistant Schizophrenia (TRS). As of March 2019, HLS had exclusive right to the device in the field of schizophrenia. Health Canada granted the Athelas One device to be marketed as CSAN® PRONTO™ and become part of the Clozaril Support and Assistance Network (CSAN) available to Canadian Institutions and healthcare providers.

Timeline

October 17, 2019

Health Canada grants medical device license for Athelas One to be marketed as CSAN® PRONTO™ by HLS Therapeutics

The device will be used for safety blood monitoring in treatment of Treatment Resistant Schizophrenia with clozapine.

November 29, 2018

A Novel Device Suitable for Home Monitoring of White Blood Cell and Neutrophil Counts (Blood (2018) 132 (Supplement 1): 1103)

Clinical third party validation of Athelas One

November 5, 2018

Athelas One, point-of-care blood monitoring device, was cleared by the FDA

August 28, 2017

Athelas receives $3.7 million in funding led by Sequoia Capital, with participation from Initialized Capital and Joe Montana’s Liquid2

June 2016

Athelas was founded

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Athelas Seed round, January 2017
5,500,000
January 2017
3 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Deepika Bodapati,

Founder

Julia Kovtoun

Employee

Nikhil Basu Trivedi

Investor

Tanay Tandon

Founder, CEO

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.